Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
Pfizer said to be discontinuing Roche-partnered hemophilia therapy Beqvez
Pfizer (PFE) discontinues Beqvez hemophilia B therapy developed with Roche (RHHBY) due to low demand, shifting focus to an ...
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
MM&M4h
BridgeBio’s stock rises on promising sales of recently approved heart drug
BridgeBio’s ATTR cardiomyopathy drug, Attruby, achieved promising sales numbers in the weeks after its FDA approval.
Paxlovid's promise fades: Vaccinated seniors see minimal COVID-19 protection
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.
FiercePharma6h
Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says
An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
pharmaphorum8h
Boehringer eyes third quarter FDA verdict for oral HER2 drug
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Endocrinology Advisor19h
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
BioSpace1d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...